Cargando…

Severity and disease control before house dust mite immunotherapy initiation: ANTARES a French observational survey

BACKGROUND: Allergen immunotherapy (AIT) may be prescribed for patients with allergic rhinitis (AR) induced by house dust mites (HDM) whether asthma is present or not. Current guidelines provide insufficient support for therapeutic management strategy of these patients. Allergists however have long-...

Descripción completa

Detalles Bibliográficos
Autores principales: Demoly, Pascal, Broué-Chabbert, Anne, Wessel, François, Chartier, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827229/
https://www.ncbi.nlm.nih.gov/pubmed/27069487
http://dx.doi.org/10.1186/s13223-016-0119-z
_version_ 1782426444219023360
author Demoly, Pascal
Broué-Chabbert, Anne
Wessel, François
Chartier, Antoine
author_facet Demoly, Pascal
Broué-Chabbert, Anne
Wessel, François
Chartier, Antoine
author_sort Demoly, Pascal
collection PubMed
description BACKGROUND: Allergen immunotherapy (AIT) may be prescribed for patients with allergic rhinitis (AR) induced by house dust mites (HDM) whether asthma is present or not. Current guidelines provide insufficient support for therapeutic management strategy of these patients. Allergists however have long-term experience with AIT. This study aims to describe the characteristics of the patients seen in clinical practice with HDM allergy and the process used to determine whether AIT should be initiated. METHODS: This was an observational, multicenter, prospective and cross-sectional study, conducted in France from 2013 to 2014 with a representative sample of allergy specialists. Any patient over 5 years of age with confirmed HDM allergy untreated with AIT within the last 12 months was eligible. Data were prospectively collected using physician and patient questionnaires. RESULTS: A total of 1589 patients (60 % adults, 40 % children) were included by 195 randomly selected allergists. A subgroup of 1212 patients (median age: 22 years; 52 % women) were selected for AIT treatment with a median time of AR diagnosis of 3 years. Amongst these, 59 % had a moderate to severe persistent AR according to AR and its Impact on Asthma guidelines, 57.5 % were polysensitized, and 56.5 % also suffered from conjunctivitis (median rhinitis total symptom score: 11). Asthma was present in 42 % of patients, and was controlled according to Global Initiative for Asthma guidelines in 62 % of patients. The asthma control questionnaire score was 1–1.5 in 20 % and ≥1.5 in 37 % of patients. A total of 57 % patients received a prescription of ≥2 medications (mainly antihistamines). Usual daily activities and sleep quality were slightly-to-moderately impaired as the mean rhinoconjunctivitis quality of life questionnaire score was 2.7 ± 1.5. The major driver of AIT prescription is AR uncontrolled by previous medications leading to patient dissatisfaction. CONCLUSIONS: HDM-AR associated conjunctivitis was present in 60 % and asthma in 40 % of cases. In >40 % of these cases, asthma was inadequately controlled at the start of AIT.
format Online
Article
Text
id pubmed-4827229
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48272292016-04-12 Severity and disease control before house dust mite immunotherapy initiation: ANTARES a French observational survey Demoly, Pascal Broué-Chabbert, Anne Wessel, François Chartier, Antoine Allergy Asthma Clin Immunol Research BACKGROUND: Allergen immunotherapy (AIT) may be prescribed for patients with allergic rhinitis (AR) induced by house dust mites (HDM) whether asthma is present or not. Current guidelines provide insufficient support for therapeutic management strategy of these patients. Allergists however have long-term experience with AIT. This study aims to describe the characteristics of the patients seen in clinical practice with HDM allergy and the process used to determine whether AIT should be initiated. METHODS: This was an observational, multicenter, prospective and cross-sectional study, conducted in France from 2013 to 2014 with a representative sample of allergy specialists. Any patient over 5 years of age with confirmed HDM allergy untreated with AIT within the last 12 months was eligible. Data were prospectively collected using physician and patient questionnaires. RESULTS: A total of 1589 patients (60 % adults, 40 % children) were included by 195 randomly selected allergists. A subgroup of 1212 patients (median age: 22 years; 52 % women) were selected for AIT treatment with a median time of AR diagnosis of 3 years. Amongst these, 59 % had a moderate to severe persistent AR according to AR and its Impact on Asthma guidelines, 57.5 % were polysensitized, and 56.5 % also suffered from conjunctivitis (median rhinitis total symptom score: 11). Asthma was present in 42 % of patients, and was controlled according to Global Initiative for Asthma guidelines in 62 % of patients. The asthma control questionnaire score was 1–1.5 in 20 % and ≥1.5 in 37 % of patients. A total of 57 % patients received a prescription of ≥2 medications (mainly antihistamines). Usual daily activities and sleep quality were slightly-to-moderately impaired as the mean rhinoconjunctivitis quality of life questionnaire score was 2.7 ± 1.5. The major driver of AIT prescription is AR uncontrolled by previous medications leading to patient dissatisfaction. CONCLUSIONS: HDM-AR associated conjunctivitis was present in 60 % and asthma in 40 % of cases. In >40 % of these cases, asthma was inadequately controlled at the start of AIT. BioMed Central 2016-04-11 /pmc/articles/PMC4827229/ /pubmed/27069487 http://dx.doi.org/10.1186/s13223-016-0119-z Text en © Demoly et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Demoly, Pascal
Broué-Chabbert, Anne
Wessel, François
Chartier, Antoine
Severity and disease control before house dust mite immunotherapy initiation: ANTARES a French observational survey
title Severity and disease control before house dust mite immunotherapy initiation: ANTARES a French observational survey
title_full Severity and disease control before house dust mite immunotherapy initiation: ANTARES a French observational survey
title_fullStr Severity and disease control before house dust mite immunotherapy initiation: ANTARES a French observational survey
title_full_unstemmed Severity and disease control before house dust mite immunotherapy initiation: ANTARES a French observational survey
title_short Severity and disease control before house dust mite immunotherapy initiation: ANTARES a French observational survey
title_sort severity and disease control before house dust mite immunotherapy initiation: antares a french observational survey
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827229/
https://www.ncbi.nlm.nih.gov/pubmed/27069487
http://dx.doi.org/10.1186/s13223-016-0119-z
work_keys_str_mv AT demolypascal severityanddiseasecontrolbeforehousedustmiteimmunotherapyinitiationantaresafrenchobservationalsurvey
AT brouechabbertanne severityanddiseasecontrolbeforehousedustmiteimmunotherapyinitiationantaresafrenchobservationalsurvey
AT wesselfrancois severityanddiseasecontrolbeforehousedustmiteimmunotherapyinitiationantaresafrenchobservationalsurvey
AT chartierantoine severityanddiseasecontrolbeforehousedustmiteimmunotherapyinitiationantaresafrenchobservationalsurvey